Basilea Pharmaceutica
As of the edition of 20 October 2026, Basilea Pharmaceutica runs 9 drugs, 3 of them marketed; it is on route A at 4 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 2 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Isavuconazole | none listed | 0 |
| Ceftobiprole | none listed | 0 |
| Ceftobiprole medocaril free acid | Ends 2034 (exclusivity) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 4 targets, route B at 0 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Basilea Pharmaceutica needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 27 trials led
- Cancer: 9 trials led
- Lungs and airways: 6 trials led